BlackRock Amends PTC Therapeutics Stake (10th Update)
Ticker: PTCT · Form: SC 13G/A · Filed: Jan 8, 2024 · CIK: 1070081
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock just updated its passive stake in PTC Therapeutics.**
AI Summary
BlackRock Inc. has updated its ownership stake in PTC Therapeutics, Inc. through an SC 13G/A filing on January 8, 2024, reflecting its holdings as of December 31, 2023. This amendment, the 10th for BlackRock, indicates a change in their passive investment, which is important for investors as BlackRock is a major institutional holder and its movements can signal shifts in confidence or strategy regarding PTC Therapeutics' common stock.
Why It Matters
This filing shows BlackRock's updated passive investment in PTC Therapeutics, which can influence market perception and potentially stock price due to the size and influence of BlackRock.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should note BlackRock's continued presence as a significant passive holder, but this routine update doesn't suggest an immediate buy or sell signal. It's a data point for understanding institutional interest.
Key Numbers
- 69366J200 — CUSIP Number (identifies the common stock of PTC Therapeutics, Inc.)
- 10 — Amendment Number (indicates this is the tenth amendment to BlackRock's Schedule 13G filing for PTC Therapeutics)
Key Players & Entities
- BlackRock Inc. (company) — the entity filing the SC 13G/A, reporting its ownership in PTC Therapeutics, Inc.
- PTC THERAPEUTICS, INC. (company) — the subject company whose common stock is being reported on
- December 31, 2023 (date) — the date of the event which required the filing of this statement
- January 8, 2024 (date) — the date the SC 13G/A filing was made
- 10 (number) — the amendment number for this SC 13G filing by BlackRock
Forward-Looking Statements
- BlackRock will continue to hold a significant, passive stake in PTC Therapeutics. (BlackRock Inc.) — high confidence, target: Q1 2025
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, indicating a change in beneficial ownership by a passive investor.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., a major asset management firm.
What company's stock is the subject of this filing?
The subject company is PTC THERAPEUTICS, INC., a pharmaceutical preparations company.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
How many amendments has BlackRock Inc. filed for PTC Therapeutics, Inc. on Schedule 13G?
This filing is Amendment No. 10, meaning BlackRock Inc. has filed ten amendments to its Schedule 13G for PTC Therapeutics, Inc.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 8, 2024 regarding PTC THERAPEUTICS, INC. (PTCT).